On Open-Label Study in Participants With Systemic Lupus Erythematosus
| Status: | Terminated |
|---|---|
| Conditions: | Lupus, Infectious Disease, Orthopedic, Endocrine |
| Therapuetic Areas: | Endocrinology, Immunology / Infectious Diseases, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/19/2018 |
| Start Date: | January 2012 |
| End Date: | October 2015 |
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)
The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399
in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
Inclusion Criteria:
- Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)
- Given written informed consent
- Test negative for pregnancy at the time of enrollment
- Agree to use a reliable method of birth control
Exclusion Criteria:
- Unwilling to comply with study procedures
- Any condition that renders the participants unable to understand the nature and scope
and possible consequences of the study
- Any condition that in the opinion of the investigator poses an unacceptable risk to
the participants if study drug would be administered
We found this trial at
1
site
Click here to add this to my saved trials
